Summary
Becton Dickinson and Company (BDX) filed its annual report on Form 10-K for the fiscal year ended September 30, 2003. The report provides a comprehensive overview of the company's business segments, operations, and financial condition. BDX operates as a global medical technology company with three primary segments: Medical, Diagnostics, and Biosciences. The Medical segment focuses on products like syringes, needles, and diabetes care devices. The Diagnostics segment offers microbiology products, specimen management systems, and diagnostic test kits. The Biosciences segment provides life science research tools, including flow cytometry systems and molecular biology products. The company emphasizes its commitment to research and development, with significant investments made over the past three fiscal years to drive product innovation and maintain a competitive edge in the dynamic medical technology market. BDX also highlights its global presence, with manufacturing and sales operations spanning numerous countries. While the company is subject to various risks and uncertainties inherent in the healthcare industry, including competition, regulatory changes, and economic factors, it maintains a strong focus on compliance and risk management.
Key Highlights
- 1BDX operates three core business segments: Medical, Diagnostics, and Biosciences, offering a diverse range of medical supplies, devices, laboratory equipment, and diagnostic products.
- 2The company made significant investments in research and development, spending approximately $235 million in fiscal year 2003 to fuel innovation.
- 3BDX maintains a global footprint with manufacturing facilities in numerous countries across Europe, Asia Pacific, and Latin America, alongside its U.S. operations.
- 4The company is actively involved in defending against several product liability lawsuits, including those related to latex gloves and needlestick injuries, with insurance coverage and reserves in place.
- 5BDX's common stock is publicly traded on the New York Stock Exchange, with a substantial market capitalization as of June 30, 2003.
- 6The company's operations are subject to regulatory oversight from agencies like the FDA and various international bodies, which BDX believes it is in material compliance with.